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Translational Research
• Current developments in basic discovery sciences have not been 
mirrored by the same level of progress in understanding the clinical 
basis of disease and ultimately the development of novel effective 
therapies. This can be improved by applying translational research 
throughout the late-stage discovery and exploratory development 
stages of drug development.
• The American Physiological Society (APS) has defined translational 
research as ‘the transfer of knowledge gained from basic research to 
new and improved methods of preventing, diagnosing, or treating 
disease, as well as the transfer of clinical insights into hypotheses 
that can be tested and validated in the basic research laboratory’.
Ref: Damian O’Connell and David Roblin; Translational research in the pharmaceutical industry: from bench to bedside;Drug Discovery Today, Volume 
11, Issues 17-18,2006, Pages 833-838 .
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Translational Research
• It is a two way process of iterative learning from experimentation.  
Within the context of the biopharmaceutical drug industry, 
translational research constitutes the cross-line preclinical and 
clinical research strategies and experiments that bridge the scientific 
and operational gaps between basic research (bench) and early-stage 
clinical studies (bedside).
• The integration of this bi-directional thought process can be 
extremely powerful. An example from bench to bedside includes 
development of clear aqueous drops of a calcineurin inhibitor for 
treatment of dry eye syndrome.
Ref: Damian O’Connell and David Roblin; Translational research in the pharmaceutical industry: from bench to bedside;Drug Discovery Today, Volume 
11, Issues 17-18,2006, Pages 833-838 .
Dry Eye: A Large and Growing 
Medical Problem
Significant Medical Need
 Chronic Inflammation of the Tear-Producing Lacrimal 
Gland
 Break-Up of Tear Film: Blurred Vision, Corneal Damage, 
Pain
 Risk Factors: Lasik, Menopause and Autoimmune Diseases
Current Therapies Fall Short
 40% of All Ophthalmologist Visits 
for Dry Eye
 10M in U.S./EU  Affected
 Sjogren’s (Dry Eye, Dry Mouth, 
Inflamed Joints) 1% of Population
 Painful, Debilitating Condition
 Palliative: OTC Artificial Tears
 Restasis® (0.05% CsA emulsion)
 Modest Efficacy
 Irritating/Burning Sensation
 Poor Compliance
Voclosporin – a Next Generation 
Calcineurin Inhibitor
• Calcineurin Inhibitors: Down-Regulate Pro-Inflammatory TH-1 Cells
• Oral Formulation
– Uveitis (Phase III, Lux Biosciences, N= 557)
– Psoriasis (Phase III Isotechnika; N = ~1,000)
– Renal Allografts (Phase IIb Isotechnika; n = 334)
• Topical Ophthalmic Formulation 
– Dry Eye, Blepharitis, Conjunctivitis (Lux Biosciences)
Background
6
 Rationally Designed Novel Molecule
 4x Greater Potency vs. Cyclosporine A
 Predictable Dosing
 Extended Therapeutic Window
FEATURES
 High Efficacy and Good Safety: Suitable for Chronic Use (Oral 
Form)
 High Efficacy and Tolerability, Good Compliance (Topical Form)
EXPECTED 
BENEFITS
Structures: Cyclosporine A & Voclosporin
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Voclosporin: Higher affinity to Calcineurin than CsA
Calcineurin
Cyclophilin A
Voclosporin
Cyclosporine A
Latch Region
Mixed NanoMicellar Formulation: 
Voclosporin
Surfactant 1
Surfactant 2
Nanomicellar structure of formulation 
Voclosporin
Vitamin E TPGS Octoxynol-40
LX-214
Voclosporin: Proprietary Topical
Product with Best-in-Class Potential
 Proprietary Topical Formulation: Clear 
Solution
 Easy to Use: Eye Drop, Single Use Vial, 
Patient Administered
Target Profile vs. Restasis
 High Tissue Concentration of Next 
Generation Calcineurin Inhibitor: Expect 
Better Efficacy
 Less Irritating than Restasis® in Animal Eyes: 
Expect Better Tolerability
 Potential for QD Dosing Based on pK Data: 
Expect Better Compliance
Voclosporin Pilot Tolerability Study 
Design
• Repeat Dose Tolerability Study
– New Zealand white Rabbits (3-4 KG)
– One drop (50 ul) of a LX214 formulation or Restasis® per eye
– LX214 formulations tested: 
• 0.2% LX214 with varying amounts of excipients (total of 12 
formulations tested: 3 Groups of 4 formulations each)
• 0.02% LX214 with varying amounts of excipients (total of 4 
formulations tested)
• n=3 eyes tested per formulation (Total n=12 eyes/group x 4 groups 
= 48 eyes)
• N=4 eyes tested for Restasis®
– Treated every 30 minutes for 4 treatments
– Hackett-MacDonald microscopic ocular examination and scoring done 
at 1, 24, & 72 hours after treatment
Voclosporin: Not Irritating to the Eye
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0.02% LX214
Mean Microscopic Ocular Exam Scores (NZW Rabbits, N=48 Eyes)
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1-Day Repeat Dose Ocular Tolerability 
Test:  Voclosporin vs. Restasis®
Four Applications (50 µL Application per Eye), Applied 30 Min Apart
LX-214 Restasis®
Voclosporin Pilot Efficacy Study 
Canine Keratoconjunctivitis Sicca
• Severe dry eye - similar to 
human dry eye
• Immune-mediated lacrimal 
gland destruction
• Clinical parameters include 
corneal vascularization, 
pigmentation, mucus 
discharge
• Schirmer tear test (STT) <10 
mm/min (normal  15-21 
mm/min)
• >85% well-controlled using 
topical CsA
Early canine KCS
Chronic canine KCS
Voclosporin Pilot Efficacy Study –
Canine KCS
Schirmer Tear Test Values (N=6)
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Voclosporin Pilot Efficacy Study 
Canine Keratoconjunctivitis Sicca
• 0.2% LX214 topically bid
– No signs of irritation or ocular toxicity up to 30 days
– No adverse reactions
• STT maintained at normal levels
– Entire 30 days
Tissue Levels After Single Dose in NZW Rabbits
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Ocular PK in Animals Supports  Q.D. 
Dosing of Voclosporin
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Voclosporin Q.D. Produces Therapeutic 
Levels In Relevant Ocular Tissues
Cmax After Multiple Topical Dose (Day 7 or Day 9, Respectively) In 
Rabbits
LX214 Q.D. Restasis® B.I.D. (Published)
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Phase I Design
A Phase 1 Dose-Escalation Study to Assess the Safety and 
Tolerability of LX214 Ophthalmic Solution in Healthy 
Volunteers, Followed by an Open-Label Evaluation of LX214 
Ophthalmic Solution in Subjects with keratoconjunctivitis sicca
• Primary Objective
– Safety and Tolerability of LX214 in healthy volunteers 
and subjects with keratoconjunctivitis sicca (KCS)
• Secondary Objective
– PK in healthy volunteers and subjects with KCS
Criteria for Evaluation of Safety and 
Tolerability
Tolerability
• Treatment-Emergent Ocular Symptomatology
Safety
• Adverse Events
• Treatment-Emergent Adverse Events
– Biomicroscopy findings
– Ophthalmoscopy findings
– External handlight examination findings
• Snellen Visual Acuity
• Intraocular Pressure
• Vital Signs
• Clinical Laboratory Evaluations
LX214 (0.2% bid) - Promising Early 
Signs of Efficacy at 2 Weeks (Signs) 
Schirmer’s Tear Test*
Normal
Increase from Screening
31% 68%
*with anesthesia
**4th Protocol amendment removed requirement for fluorescein staining 
LX214 (0.2% bid) - Promising Early Signs of 
Efficacy at 2 Weeks (Symptoms) 
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Reduction in Score From Baseline
32% 48% 27% 15%
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LX214 - Efficacy Comparison to 
Restasis®
Restasis – Schirmer’s
• Phase II (12 weeks)
– Mean Baseline 2.4 – 3.1 mm/5min
– 0.1% concentration - mean 
increase 4.3 (week 8) 2.8 mm 
(week 12)
• Phase III (6 months)
LX214 - Schirmer’s 
• Phase I (2 weeks)
– Mean Baseline 5.8mm/5min 
(left eye) and 4.4mm/5min 
(right eye)
– Mean improvement 
– Categorized improvements
– 0.05% (Restasis), +0.9 and +0.4 
(month 3 and 6)
– 0.1% concentration, -0.1 and +0.3 
(month 3 and 6)
• Safety Extension (1 year)
– Mean Baseline 5.8mm/5min
– 0.1% concentration - mean 
improvement 0.4mm/5min 
(n=278) 
1.8mm/5min (left eye) and 
3mm/min (right eye)
– Categorized improvements, 
worse eye +5
Patients Entered Study with a High Degree 
Of Symptomatology
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0= None of the time, 1= Some of the time, 2= Half the time, 3= Most of the time, 4= All of the time
Patients Experienced a Decease In 
Symptomatology with LX214
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Low Rate of Ocular Treatment Related Side 
Effects in A Highly Symptomatic Disease
3/5 Patients reported one or more AEs
* One patient entered the trial with pre-existing hyperemia
LX214 Phase I Conclusions
In short-term exposure
• Tolerability in healthy volunteers similar to placebo
• No apparent effect on intraocular pressure
• Blood levels well below threshold level defined by FDA 
(not requiring sampling in future studies)
• Intriguing hint of efficacy in the small patient population
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